What is Leerink Partnrs' Forecast for TRVI FY2024 Earnings?

Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) - Investment analysts at Leerink Partnrs dropped their FY2024 EPS estimates for Trevi Therapeutics in a research note issued to investors on Tuesday, January 21st. Leerink Partnrs analyst F. Khurshid now expects that the company will post earnings of ($0.49) per share for the year, down from their previous estimate of ($0.48). The consensus estimate for Trevi Therapeutics' current full-year earnings is ($0.49) per share. Leerink Partnrs also issued estimates for Trevi Therapeutics' Q1 2025 earnings at ($0.13) EPS, Q2 2025 earnings at ($0.13) EPS, Q3 2025 earnings at ($0.12) EPS, Q4 2025 earnings at ($0.12) EPS, FY2025 earnings at ($0.49) EPS and FY2026 earnings at ($0.48) EPS.

A number of other research firms have also issued reports on TRVI. B. Riley restated a "buy" rating and set a $6.00 price target on shares of Trevi Therapeutics in a report on Monday, October 7th. Needham & Company LLC reissued a "buy" rating and set a $8.00 target price on shares of Trevi Therapeutics in a research note on Thursday, December 12th. HC Wainwright increased their price objective on Trevi Therapeutics from $6.00 to $7.50 and gave the stock a "buy" rating in a report on Thursday, December 12th. Finally, D. Boral Capital reissued a "buy" rating and set a $21.00 price objective on shares of Trevi Therapeutics in a research report on Wednesday, January 8th. Eight research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, Trevi Therapeutics presently has a consensus rating of "Buy" and a consensus price target of $9.31.

Trevi Therapeutics Stock Performance

Shares of NASDAQ:TRVI traded up $0.23 during mid-day trading on Thursday, hitting $4.01. The stock had a trading volume of 324,214 shares, compared to its average volume of 538,832. The company's 50 day moving average is $3.54 and its 200-day moving average is $3.20. Trevi Therapeutics has a 12-month low of $1.31 and a 12-month high of $4.68. The company has a market cap of $307.86 million, a PE ratio of -9.11 and a beta of 0.87.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.01). During the same quarter in the prior year, the business earned ($0.08) EPS.

Institutional Trading of Trevi Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets raised its position in shares of Trevi Therapeutics by 130.9% during the third quarter. BNP Paribas Financial Markets now owns 11,930 shares of the company's stock valued at $40,000 after buying an additional 6,764 shares during the last quarter. Hsbc Holdings PLC bought a new stake in shares of Trevi Therapeutics in the 2nd quarter worth approximately $61,000. Intech Investment Management LLC bought a new stake in shares of Trevi Therapeutics in the 3rd quarter worth approximately $63,000. The Manufacturers Life Insurance Company grew its holdings in shares of Trevi Therapeutics by 87.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 24,524 shares of the company's stock worth $73,000 after purchasing an additional 11,450 shares in the last quarter. Finally, SG Americas Securities LLC bought a new stake in shares of Trevi Therapeutics during the third quarter valued at approximately $78,000. Institutional investors and hedge funds own 95.76% of the company's stock.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.